HYK华因康品牌怎么样 申请店铺

我要投票 HYK华因康在基因检测行业中的票数:85 更新时间:2025-01-22
HYK华因康是哪个国家的品牌?「HYK华因康」是 深圳华因康基因科技有限公司 旗下著名品牌。该品牌发源于广东,由创始人盛司在2008-01-23期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
HYK华因康怎么样

华因康集团秉承“专业、严谨、创新、服务”的理念,自2008年创立以来,一直致力于中华民族健康事业,发展迅猛。迄今拥有深圳市华因康高通量生物技术研究院、深圳华因康基因科技有限公司、华因康基因检测中心及全国各地多家分支机构,成为以基因技术为核心,拥有雄厚研发支撑、具备研发、生产和应用三位一体的完整产业链的生物技术高科技集团。

研发中心–深圳市华因康高通量生物技术研究院拥有一支在机械、光学、电子、生化、软件、生物信息、生物医疗等技术领域具备尖端技术成果的科学家、教授、博士、博士后及行业专家组成的精英技术团队。研究院面向世界科学前沿和国家战略发展需求,以新型DNA测序分析技术的突破为契机,旨在研究高通量生物技术,开发高通量实验和检测设备,寻找高通量检测新方法,为我国生命科技领域的上游进行产业布局,搭建与基因技术相关的生命科技产业基础性研究平台,进行国际前沿基因组科学基础及应用研究与技术开发,提升我国基因技术自主创新能力。

产品中心-深圳华因康基因科技有限公司专业生产、销售高通量基因测序设备、生物试剂和基因信息分析软件,提供科研技术服务与生物信息数据分析技术服务。公司主导产品PSTAR高通量基因测序系统,填补了我国在生命科技产业核心装备、基因测序设备制造、试剂生产与生物信息分析服务等领域的空白,广泛应用于生命科学基础研究、临床诊断与治疗、疾病预防与保健以及新药研制等领域。

基因检测中心-华因康基因检测中心依托于华因康基因新一代高通量基因测序系统平台技术,是转化医学的专业化服务机构。中心以新一代高通量基因测序系统技术平台为核心,辅以实时荧光PCR平台、STR分析平台、免疫组化、荧光原位杂交等技术平台,覆盖了DNA、RNA、蛋白水平,测序、PCR、蛋白免疫组化、FISH等多种检测技术。已率先研发出多种适用于亚洲人的临床基因检测项目,专业提供“肿瘤个体化用药指导靶基因检测”临床技术服务,同时为临床提供疾病早期筛查、重大疾病分子标志物检测及与保健、优生优育相关的检测服务。与国内顶级医院及科研机构携手,开拓高通量基因测序技术在生命科学与医疗健康领域中的广阔应用,为人类的健康事业提供专业、贴心的个性化服务。

华因康基因(集团)将始终坚持“探索基因信息,提高生命价值”的宗旨,致力于打造基因生命科技在研发、应用、临床转化系统平台技术上的核心竞争力,彰显中国基因产业在世界竞争中的领航者地位,引领中国健康产业发展新方向。


Huayinkang group adheres to the concept of "professional, rigorous, innovative and service". Since its establishment in 2008, it has been committed to the cause of health of the Chinese nation, with rapid development. So far, it has Shenzhen huayinkang high throughput Biotechnology Research Institute, Shenzhen huayinkang Gene Technology Co., Ltd., huayinkang gene testing center and many branches all over the country. It has become a biotechnology high-tech group with gene technology as the core, strong R & D support, and a complete industrial chain of R & D, production and application. R & D Center - Shenzhen huayinkang high throughput Biotechnology Research Institute has an elite technical team composed of scientists, professors, doctors, postdoctors and industry experts with cutting-edge technical achievements in the fields of machinery, optics, electronics, biochemistry, software, biological information, biomedicine and other technical fields. Facing the needs of the world's scientific frontier and national strategic development, and taking the breakthrough of new DNA sequencing analysis technology as an opportunity, the research institute aims to study high-throughput biotechnology, develop high-throughput experiment and detection equipment, find new high-throughput detection methods, make industrial layout for the upstream of China's life science and technology field, and build a basic research platform of life science and technology industry related to gene technology To carry out basic and applied research and technological development of international frontier genomic science and improve the independent innovation ability of China's gene technology. Product Center - Shenzhen huayinkang Gene Technology Co., Ltd. specializes in the production and sales of high-throughput gene sequencing equipment, biological reagents and gene information analysis software, providing scientific research and technical services and biological information data analysis technical services. The company's leading product, pstar high-throughput gene sequencing system, has filled in the gaps in the core equipment of life science and technology industry, gene sequencing equipment manufacturing, reagent production and bio information analysis services in China, and is widely used in basic research of life science, clinical diagnosis and treatment, disease prevention and health care, and new drug development and other fields. Based on the platform technology of new generation high-throughput gene sequencing system of huayinkang gene, huayinkang gene testing center is a professional transformation medicine service organization. The center takes the new generation high-throughput gene sequencing system technology platform as the core, supplemented by real-time fluorescent PCR platform, STR analysis platform, immunohistochemistry, fluorescence in situ hybridization and other technology platforms, covering DNA, RNA, protein level, sequencing, PCR, protein immunohistochemistry, fish and other detection technologies. It has taken the lead in developing a variety of clinical gene detection projects suitable for Asians, providing professional clinical technical services of "tumor individualized drug use guidance target gene detection", and providing early disease screening, detection of major disease molecular markers and detection services related to health care, eugenics and eugenics. Together with the top domestic hospitals and scientific research institutions, we will explore the wide application of high-throughput gene sequencing technology in the field of life science and medical health, and provide professional and intimate personalized services for human health. Huayinkang gene (Group) will always adhere to the tenet of "exploring gene information and improving life value", devote itself to building the core competitiveness of gene life technology in research and development, application and clinical transformation system platform technology, highlight the leading position of China's gene industry in the world competition, and lead the new development direction of China's health industry.

本文链接: https://brand.waitui.com/4c1ad289a.html 联系电话:075526611270

千城特选小程序码

7×24h 快讯

英国政府借款大幅增加,遵守财政规则面临挑战

英国政府2024年12月预算赤字激增,在利率居高不下、经济增长疲软的情况下,英国政府在遵守财政规则方面面临挑战。英国国家统计局周三表示,12月政府支出超过收入178亿英镑(219.9亿美元),赤字比去年同期高出101亿英镑,远高于预算责任办公室预测的142亿英镑。推动这一增长的一个因素是利息支付,比2023年同期高出38亿英镑。(新浪财经)

2小时前

策源资本旗下基金入股灵童机器人

36氪获悉,天眼查App显示,近日,灵童机器人(上海)有限公司发生工商变更,新增成都策源广益数字经济股权投资基金合伙企业(有限合伙)、成都高新策源共创企业管理咨询合伙企业(有限合伙)为股东,同时注册资本由103万人民币增至约115.9万人民币。灵童机器人(上海)有限公司成立于2022年8月,法定代表人为陆杰,经营范围含智能机器人的研发、智能机器人销售、服务消费机器人销售、人工智能硬件销售、人工智能应用软件开发、数字内容制作服务等。

2小时前

百万tokens降价至0.8元后,豆包模型毛利率已能达到50%

从多个知情人士处获悉,豆包大模型去年大幅降价后,毛利率依然为正。其中,字节跳动最新推出的豆包大模型1.5,在推理成本优化上取得进一步突破。在火山引擎上售卖API的Doubao-1.5-pro,毛利率仍能达到50%。去年5月,字节跳动正式对外发布豆包大模型。其中,豆包通用模型pro-32k版,模型推理输入价格仅每百万tokens0.8元,而当时市场上同规格模型的定价一般为每百万tokens120元,是豆包模型价格的150倍。(界面)

2小时前

华林证券:2024年净利同比预增973.03%—1288.62%

36氪获悉,华林证券发布业绩预告,预计2024年归母净利3.4亿元—4.4亿元,同比增长973.03%—1288.62%。公司持续推进科技金融转型战略,财富管理线上业务收入同比大幅增加。自营投资业务积极把握市场机遇,进一步提升配置资产能力,收入大幅增加。此外,公司针对红博会展信托受益权资产支持专项计划仲裁事项,于2023年度计提预计负债约2.28亿元,导致2024年度相关营业外支出同比大幅下降。该笔营业外支出为非经常性损益。

2小时前

北京君羊商贸有限公司获千万级Pre-A轮融资

36氪获悉,近日,北京君羊商贸有限公司宣布获得腾信投资领投的Pre-A轮千万级融资。公司创始人邵群表示,本轮融资资金主要投入到开拓业务、技术创新和拓宽市场这三大核心领域,同时将投入大量资金用于AI 算法的优化和模型训练。

2小时前

本页详细列出关于TIANDZ的品牌信息,含品牌所属公司介绍,TIANDZ所处行业的品牌地位及优势。
咨询